Navigation Links
SNM clinical trials network expands phantom program for evaluating imaging centers
Date:4/14/2009

Reston, Va.The SNM Clinical Trials Network has announced that a prototype clinical PET oncology imaging simulatoror "phantom"has been successfully scanned and imaged at four imaging centers. SNM intends to deliver and scan the phantom at an additional 20 imaging centers by the end of September.

SNM's Clinical Trials Networkas part of its mission to ensure standardization and harmonization across multiple imaging sites participating in clinical trialsevaluates images produced by phantoms to ensure that molecular imaging centers are providing consistent and accurate images. Imaging consistency among sitesboth in the technology used and images producedis critical for ensuring quality imaging and quantitative data and is essential to meet Food and Drug Administration (FDA) requirements for investigational clinical trials.

"The community agrees that a lack of uniformity across imaging sites is a primary barrier to using imaging in clinical trials to facilitate drug development," said Michael Graham, Ph.D., M.D., co-chair of SNM's Clinical Trials Network and director of nuclear medicine at the University of Iowa Carver College of Medicine. "When pharmaceutical companies apply to FDA for approval of a new product, they must first demonstrate a certain level of disease detectability as evidenced by some imaging measurement. Many of the denials of new drugs are based on a rejection of data compiled from poor-quality images or images that don't appear to match those from another similar study."

Successfully scanning phantoms is one part of the overall process that the network will use to "validate" imaging sites for future clinical trials. Imaging of the PET phantoms, which contain a known quantity and distribution of radioactivity, will be used to evaluate each site's imaging capabilities both qualitatively and quantitatively and ensure standardization and compliance with defined protocols in order to ensure consistency across multiple centers in a single trial.

"The network's phantom program draws upon an SNM phantom imaging program that has been operational for over ten years. In addition, SNM maintains a group of experts who evaluate a center's image quality," said Paul E. Christian, chair of the Clinical Trials Network's Phantom Subcommittee and associate director of molecular imaging at the Huntsman Cancer Institute, University of Utah. "Based on these phantom images, experts can help imaging centers by recommending adjustments in the image acquisition parameters to produce images of a very high quality."

The first phantom in use is the oncology phantom (designed primarily to support investigational oncology clinical trials), which was scanned at each of four test sitesthe University of Utah, University of Iowa, University of Pennsylvania and Mayo Clinicusing a standard imaging protocol. To test the resolution of the imaging equipment at each site, the phantom contained multiple simulated tumors of different sizes. Physicians at each of the four sites were able to evaluate the images and identify all the tumors.

Based on this initial success with the oncology phantom, the network is expanding its phantom imaging program by providing other phantoms to qualified sites in the network's registry. In this regard, a cardiac phantom is beginning testing at the four initial sites, and a brain phantom prototype is being developed and is anticipated to be available by June to assist a pharmaceutical company with site imaging evaluation for an upcoming phase 3 clinical trial. These three phantoms will be on display at the MI Gateway in the exhibit hall during SNM's 56th Annual Meeting, June 13󈝽, Toronto, Canada.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology: